Company intelligence / Profile preview

Argolyn Bioscience

Durham, North Carolina, USA

Ownership: Private
Development stage: Other

Overview

Argolyn Bioscience was a biopharmaceutical company based in North Carolina that specialized in the development of stabilized peptide therapies. The company's core technology involved a proprietary method for modifying peptides to resist enzymatic degradation, thereby extending their half-life in the bloodstream. Their primary development candidate, ABS-201, was a neurotensin analog aimed at treating schizophrenia by modulating dopamine pathways without the side effects of traditional antipsychotics. Argolyn successfully advanced ABS-201 into Phase 1 clinical trials before the company ceased operations.

Therapeutic areas: PsychiatryNeurology
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on Argolyn Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Argolyn Bioscience.

Explore the full profile